{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T06:39:53Z","timestamp":1764571193248,"version":"3.41.0"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,6,5]],"date-time":"2025-06-05T00:00:00Z","timestamp":1749081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,6,5]],"date-time":"2025-06-05T00:00:00Z","timestamp":1749081600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"the Synergistic treatment of prostate cancer with a bilayer bionic nanocarrier system grant","award":["(JSWSRCZX2020-003)"],"award-info":[{"award-number":["(JSWSRCZX2020-003)"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Bladder cancer is the most common malignant tumor of the urinary tract. In this study, 90 lupane triterpene derivatives, previously synthesized in the laboratory, were systematically evaluated for their potential effects against bladder cancer by cytotoxicity screening against five urinary tumor cell lines. Bioinformatics and molecular dynamics methods were used to investigate the mechanism of action of compound 27 in depth. Most of the derivatives effectively inhibited tumor cell growth, and structure\u2013activity relationship analysis revealed that introducing an indole moiety significantly enhanced the biological activity. The peak activity was reached when the dibromoalkyl chain length was C\u2009=\u20095 (IC<jats:sub>50<\/jats:sub>\u2009=\u20091.121\u00a0\u03bcM). By integrating transcriptomic data and TCGA findings, we identified 11 key targets, among which <jats:italic>DUSP5<\/jats:italic>\u00a0and <jats:italic>SCG2<\/jats:italic>\u00a0showed significant differential expression. Further analysis revealed meaningful insights into the clinical association, 10-year survival prognosis, and immune infiltration. The present study further clarified the effects of compound 27 on the expression of <jats:italic>DUSP5<\/jats:italic> and <jats:italic>SCG2<\/jats:italic> in tumor cells after treatment by a combination of RNA-seq and RT-qPCR. Molecular docking confirmed the stable binding of compound 27 to <jats:italic>DUSP5<\/jats:italic>, which was confirmed by molecular dynamics simulations. Compound 27 inhibited bladder cancer progression by upregulating <jats:italic>DUSP5<\/jats:italic>\u00a0expression and negatively regulating the p38 MAPK pathway, modulating the immune response and promoting apoptosis.<\/jats:p>","DOI":"10.1038\/s41598-025-04855-y","type":"journal-article","created":{"date-parts":[[2025,6,5]],"date-time":"2025-06-05T03:22:13Z","timestamp":1749093733000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Design and synthesis of 3,4-seco-lupane triterpene-tryptamine derivatives and revealing their anti-bladder cancer mechanisms by combining TCGA and transcriptomic approaches"],"prefix":"10.1038","volume":"15","author":[{"given":"Qinglong","family":"Chi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongbo","family":"Teng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yaru","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xv","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiexin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huiyue","family":"Shen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuan","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chunxi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,6,5]]},"reference":[{"key":"4855_CR1","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2022.1036722","author":"B Othmane","year":"2022","unstructured":"Othmane, B. et al. Filling the gaps in the research about second primary malignancies after bladder cancer: Focus on race and histology. Front. Public Health https:\/\/doi.org\/10.3389\/fpubh.2022.1036722 (2022).","journal-title":"Front. Public Health"},{"key":"4855_CR2","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung, H. et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 71, 209\u2013249. https:\/\/doi.org\/10.3322\/caac.21660 (2021).","journal-title":"CA Cancer J. Clin."},{"key":"4855_CR3","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2023-076743","volume":"384","author":"A Lopez-Beltran","year":"2024","unstructured":"Lopez-Beltran, A., Cookson, M. S., Guercio, B. J. & Cheng, L. Advances in diagnosis and treatment of bladder cancer. BMJ 384, e076743. https:\/\/doi.org\/10.1136\/bmj-2023-076743 (2024).","journal-title":"BMJ"},{"key":"4855_CR4","doi-asserted-by":"publisher","first-page":"5562","DOI":"10.2174\/0929867326666190816230650","volume":"27","author":"M He","year":"2020","unstructured":"He, M., Xuehong, C. & Yepeng, L. Small molecular gemcitabine prodrugs for cancer therapy. Curr. Med. Chem. 27, 5562\u20135582. https:\/\/doi.org\/10.2174\/0929867326666190816230650 (2020).","journal-title":"Curr. Med. Chem."},{"key":"4855_CR5","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1007\/s11306-018-1452-7","volume":"14","author":"T Gebregiworgis","year":"2018","unstructured":"Gebregiworgis, T. et al. Insights into gemcitabine resistance and the potential for therapeutic monitoring. Metabolomics 14, 156. https:\/\/doi.org\/10.1007\/s11306-018-1452-7 (2018).","journal-title":"Metabolomics"},{"key":"4855_CR6","doi-asserted-by":"publisher","first-page":"325","DOI":"10.3390\/ph13100325","volume":"13","author":"M Hilmi","year":"2020","unstructured":"Hilmi, M. et al. Cardiotoxicity associated with gemcitabine: literature review and a pharmacovigilance study. Pharmaceuticals 13, 325 (2020).","journal-title":"Pharmaceuticals"},{"key":"4855_CR7","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1038\/s41585-023-00847-7","volume":"21","author":"CC Guo","year":"2024","unstructured":"Guo, C. C. et al. Molecular profile of bladder cancer progression to clinically aggressive subtypes. Nat. Rev. Urol. 21, 391\u2013405. https:\/\/doi.org\/10.1038\/s41585-023-00847-7 (2024).","journal-title":"Nat. Rev. Urol."},{"key":"4855_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jddst.2020.101535","volume":"56","author":"K Yu","year":"2020","unstructured":"Yu, K., Liu, M., Dai, H. & Huang, X. Targeted drug delivery systems for bladder cancer therapy. J. Drug Deliv. Sci. Technol. 56, 101535. https:\/\/doi.org\/10.1016\/j.jddst.2020.101535 (2020).","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"4855_CR9","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1007\/s12032-022-01751-7","volume":"39","author":"Y Wang","year":"2022","unstructured":"Wang, Y. et al. Rad54L promotes bladder cancer progression by regulating cell cycle and cell senescence. Med. Oncol. 39, 185. https:\/\/doi.org\/10.1007\/s12032-022-01751-7 (2022).","journal-title":"Med. Oncol."},{"key":"4855_CR10","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1002\/tox.22734","volume":"34","author":"C-H Chiang","year":"2019","unstructured":"Chiang, C.-H., Chung, J.-G. & Hsu, F.-T. Regorefenib induces extrinsic\/intrinsic apoptosis and inhibits MAPK\/NF-\u03baB-modulated tumor progression in bladder cancer in vitro and in vivo. Environ. Toxicol. 34, 679\u2013688. https:\/\/doi.org\/10.1002\/tox.22734 (2019).","journal-title":"Environ. Toxicol."},{"key":"4855_CR11","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1186\/s12957-016-0890-9","volume":"14","author":"J Du","year":"2016","unstructured":"Du, J., Wang, S.-H., Yang, Q., Chen, Q.-Q. & Yao, X. p53 status correlates with the risk of progression in stage T1 bladder cancer: a meta-analysis. World J. Surg. Oncol. 14, 137. https:\/\/doi.org\/10.1186\/s12957-016-0890-9 (2016).","journal-title":"World J. Surg. Oncol."},{"key":"4855_CR12","doi-asserted-by":"publisher","first-page":"9304552","DOI":"10.1155\/2022\/9304552","volume":"2022","author":"X Li","year":"2022","unstructured":"Li, X. et al. Gypenoside-induced apoptosis via the PI3K\/AKT\/mTOR signaling pathway in bladder cancer. Biomed. Res. Int. 2022, 9304552. https:\/\/doi.org\/10.1155\/2022\/9304552 (2022).","journal-title":"Biomed. Res. Int."},{"key":"4855_CR13","doi-asserted-by":"publisher","first-page":"4453","DOI":"10.3892\/ol.2017.6013","volume":"13","author":"S Li","year":"2017","unstructured":"Li, S. et al. Oxymatrine inhibits proliferation of human bladder cancer T24 cells by inducing apoptosis and cell cycle arrest. Oncol. Lett. 13, 4453\u20134458. https:\/\/doi.org\/10.3892\/ol.2017.6013 (2017).","journal-title":"Oncol. Lett."},{"key":"4855_CR14","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s13075-023-03241-1","volume":"26","author":"D Kim","year":"2024","unstructured":"Kim, D. et al. Inhibitory effects of Acanthopanax sessiliflorus Harms extract on the etiology of rheumatoid arthritis in a collagen-induced arthritis mouse model. Arthritis Res. Ther. 26, 11. https:\/\/doi.org\/10.1186\/s13075-023-03241-1 (2024).","journal-title":"Arthritis Res. Ther."},{"key":"4855_CR15","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s13765-024-00912-8","volume":"67","author":"G-D Kim","year":"2024","unstructured":"Kim, G.-D., Lee, J. & Auh, J.-H. Metabolomic screening of anti-inflammatory compounds in Acanthopanax sessiliflorus fruit (Ogaza) extract. Appl. Biol. Chem. 67, 56. https:\/\/doi.org\/10.1186\/s13765-024-00912-8 (2024).","journal-title":"Appl. Biol. Chem."},{"key":"4855_CR16","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1007\/BF03179929","volume":"26","author":"S Lee","year":"2003","unstructured":"Lee, S., Shin, D.-S., Oh, K.-B. & Shin, K. H. Antibacterial compounds from the leaves of Acanthopanax senticosus. Arch. Pharmacal. Res. 26, 40\u201342. https:\/\/doi.org\/10.1007\/BF03179929 (2003).","journal-title":"Arch. Pharmacal. Res."},{"key":"4855_CR17","doi-asserted-by":"publisher","first-page":"3283","DOI":"10.1002\/jsfa.9541","volume":"99","author":"X Bian","year":"2019","unstructured":"Bian, X. et al. Hepatoprotective effect of chiisanoside from Acanthopanax sessiliflorus against LPS\/D-GalN-induced acute liver injury by inhibiting NF-\u03baB and activating Nrf2\/HO-1 signaling pathways. J. Sci. Food Agric. 99, 3283\u20133290. https:\/\/doi.org\/10.1002\/jsfa.9541 (2019).","journal-title":"J. Sci. Food Agric."},{"key":"4855_CR18","doi-asserted-by":"publisher","first-page":"41640","DOI":"10.1039\/C7RA08041G","volume":"7","author":"X Bian","year":"2017","unstructured":"Bian, X. et al. Chiisanoside, a triterpenoid saponin, exhibits anti-tumor activity by promoting apoptosis and inhibiting angiogenesis. RSC Adv. 7, 41640\u201341650. https:\/\/doi.org\/10.1039\/C7RA08041G (2017).","journal-title":"RSC Adv."},{"key":"4855_CR19","doi-asserted-by":"publisher","first-page":"25720","DOI":"10.1021\/acs.jafc.4c07994","volume":"72","author":"H Teng","year":"2024","unstructured":"Teng, H. et al. Chiisanoside from the leaves of Acanthopanax sessiliflorus can resist cisplatin-induced ototoxicity by maintaining cytoskeletal homeostasis and inhibiting ferroptosis. J. Agric. Food Chem. 72, 25720\u201325742. https:\/\/doi.org\/10.1021\/acs.jafc.4c07994 (2024).","journal-title":"J. Agric. Food Chem."},{"key":"4855_CR20","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1080\/14786419.2020.1844698","volume":"36","author":"H Wang","year":"2022","unstructured":"Wang, H. et al. Cytotoxic and anti-tumor effects of 3,4-seco-lupane triterpenoids from the leaves of Eleutherococcus sessiliflorus against hepatocellular carcinoma. Nat. Prod. Res. 36, 1062\u20131066. https:\/\/doi.org\/10.1080\/14786419.2020.1844698 (2022).","journal-title":"Nat. Prod. Res."},{"key":"4855_CR21","doi-asserted-by":"publisher","DOI":"10.1111\/acel.13041","volume":"18","author":"K Chatsirisupachai","year":"2019","unstructured":"Chatsirisupachai, K., Palmer, D., Ferreira, S. & de Magalh\u00e3es, J. P. A human tissue-specific transcriptomic analysis reveals a complex relationship between aging, cancer, and cellular senescence. Aging Cell 18, e13041. https:\/\/doi.org\/10.1111\/acel.13041 (2019).","journal-title":"Aging Cell"},{"key":"4855_CR22","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1586\/14737159.2015.1105133","volume":"15","author":"M Sager","year":"2015","unstructured":"Sager, M. et al. Transcriptomics in cancer diagnostics: developments in technology, clinical research and commercialization. Expert Rev. Mol. Diagn. 15, 1589\u20131603. https:\/\/doi.org\/10.1586\/14737159.2015.1105133 (2015).","journal-title":"Expert Rev. Mol. Diagn."},{"key":"4855_CR23","doi-asserted-by":"publisher","DOI":"10.1002\/cbdv.202000830","volume":"18","author":"H Wang","year":"2021","unstructured":"Wang, H. et al. Potential myocardial protection of 3,4-seco-lupane triterpenoids from Acanthopanax sessiliflorus leaves. Chem. Biodivers. 18, e2000830. https:\/\/doi.org\/10.1002\/cbdv.202000830 (2021).","journal-title":"Chem. Biodivers."},{"key":"4855_CR24","doi-asserted-by":"publisher","first-page":"10014","DOI":"10.1021\/acs.jmedchem.2c00664","volume":"65","author":"H Wang","year":"2022","unstructured":"Wang, H. et al. Seco-lupane triterpene derivatives induce ferroptosis through GPX4\/ACSL4 axis and target cyclin D1 to block the cell cycle. J. Med. Chem. 65, 10014\u201310044. https:\/\/doi.org\/10.1021\/acs.jmedchem.2c00664 (2022).","journal-title":"J. Med. Chem."},{"key":"4855_CR25","doi-asserted-by":"publisher","first-page":"8051","DOI":"10.1007\/s00432-022-04501-4","volume":"149","author":"D Liu","year":"2023","unstructured":"Liu, D. et al. Small molecule inhibitors for cancer metabolism: promising prospects to be explored. J. Cancer Res. Clin. Oncol. 149, 8051\u20138076. https:\/\/doi.org\/10.1007\/s00432-022-04501-4 (2023).","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"4855_CR26","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1007\/s10555-010-9265-9","volume":"29","author":"M Shi","year":"2010","unstructured":"Shi, M., Liu, D., Duan, H., Shen, B. & Guo, N. Metastasis-related miRNAs, active players in breast cancer invasion, and metastasis. Cancer Metastasis Rev. 29, 785\u2013799. https:\/\/doi.org\/10.1007\/s10555-010-9265-9 (2010).","journal-title":"Cancer Metastasis Rev."},{"key":"4855_CR27","doi-asserted-by":"publisher","first-page":"2016","DOI":"10.1016\/j.bbcan.2016.10.002","volume":"300\u2013319","author":"O Menyh\u00e1rt","year":"1866","unstructured":"Menyh\u00e1rt, O. et al. Guidelines for the selection of functional assays to evaluate the hallmarks of cancer. Biochim. Biophys. Acta Rev. Cancer 300\u2013319, 2016. https:\/\/doi.org\/10.1016\/j.bbcan.2016.10.002 (1866).","journal-title":"Biochim. Biophys. Acta Rev. Cancer"},{"key":"4855_CR28","doi-asserted-by":"publisher","first-page":"1947","DOI":"10.1002\/pro.3715","volume":"28","author":"M Kanehisa","year":"2019","unstructured":"Kanehisa, M. Toward understanding the origin and evolution of cellular organisms. Protein Sci. 28, 1947\u20131951 (2019).","journal-title":"Protein Sci."},{"key":"4855_CR29","doi-asserted-by":"publisher","first-page":"D672","DOI":"10.1093\/nar\/gkae909","volume":"53","author":"M Kanehisa","year":"2025","unstructured":"Kanehisa, M., Furumichi, M., Sato, Y., Matsuura, Y. & Ishiguro-Watanabe, M. KEGG: Biological systems database as a model of the real world. Nucleic Acids Res. 53, D672\u2013D677 (2025).","journal-title":"Nucleic Acids Res."},{"key":"4855_CR30","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1093\/nar\/28.1.27","volume":"28","author":"M Kanehisa","year":"2000","unstructured":"Kanehisa, M. & Goto, S. KEGG: Kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 28, 27\u201330 (2000).","journal-title":"Nucleic Acids Res."},{"key":"4855_CR31","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/j.eururo.2015.08.037","volume":"69","author":"J Dobruch","year":"2016","unstructured":"Dobruch, J. et al. Gender and bladder cancer: A collaborative review of etiology, biology, and outcomes. Eur. Urol. 69, 300\u2013310. https:\/\/doi.org\/10.1016\/j.eururo.2015.08.037 (2016).","journal-title":"Eur. Urol."},{"key":"4855_CR32","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1002\/jmri.27090","volume":"52","author":"I Caglic","year":"2020","unstructured":"Caglic, I. et al. MRI of bladder cancer: Local and nodal staging. J. Magn. Reson. Imaging 52, 649\u2013667. https:\/\/doi.org\/10.1002\/jmri.27090 (2020).","journal-title":"J. Magn. Reson. Imaging"},{"key":"4855_CR33","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1038\/s41389-023-00489-9","volume":"12","author":"B Doshi","year":"2023","unstructured":"Doshi, B., Athans, S. R. & Woloszynska, A. Biological differences underlying sex and gender disparities in bladder cancer: Current synopsis and future directions. Oncogenesis 12, 44. https:\/\/doi.org\/10.1038\/s41389-023-00489-9 (2023).","journal-title":"Oncogenesis"},{"key":"4855_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2024.104536","volume":"204","author":"Z-Z Li","year":"2024","unstructured":"Li, Z.-Z., Zhou, K., Wu, Q., Liu, B. & Bu, L.-L. Lymph node metastasis in cancer: Clearing the clouds to see the dawn. Crit. Rev. Oncol. Hematol. 204, 104536. https:\/\/doi.org\/10.1016\/j.critrevonc.2024.104536 (2024).","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"4855_CR35","doi-asserted-by":"publisher","first-page":"1980","DOI":"10.1001\/jama.2020.17598","volume":"324","author":"AT Lenis","year":"2020","unstructured":"Lenis, A. T., Lec, P. M., Chamie, K. & Mshs, M. Bladder cancer: A review. JAMA 324, 1980\u20131991. https:\/\/doi.org\/10.1001\/jama.2020.17598 (2020).","journal-title":"JAMA"},{"key":"4855_CR36","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/j.eururo.2023.04.004","volume":"84","author":"P Khetrapal","year":"2023","unstructured":"Khetrapal, P. et al. Robot-assisted radical cystectomy versus open radical cystectomy: A systematic review and meta-analysis of perioperative, oncological, and quality of life outcomes using randomized controlled trials. Eur. Urol. 84, 393\u2013405. https:\/\/doi.org\/10.1016\/j.eururo.2023.04.004 (2023).","journal-title":"Eur. Urol."},{"key":"4855_CR37","doi-asserted-by":"publisher","unstructured":"Conroy, S. et al. Real-world outcomes for high-risk non-muscle-invasive bladder cancer: screened patients for the BRAVO trial. BJU Int. n\/a https:\/\/doi.org\/10.1111\/bju.16516.","DOI":"10.1111\/bju.16516"},{"key":"4855_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2021.107906","volume":"98","author":"F Sun","year":"2021","unstructured":"Sun, F. et al. The MAPK dual specific phosphatase (DUSP) proteins: A versatile wrestler in T cell functionality. Int. Immunopharmacol. 98, 107906. https:\/\/doi.org\/10.1016\/j.intimp.2021.107906 (2021).","journal-title":"Int. Immunopharmacol."},{"key":"4855_CR39","doi-asserted-by":"publisher","first-page":"738","DOI":"10.7150\/ijms.24981","volume":"15","author":"T Liu","year":"2018","unstructured":"Liu, T. et al. The suppression of DUSP5 expression correlates with paclitaxel resistance and poor prognosis in basal-like breast cancer. Int. J. Med. Sci. 15, 738\u2013747. https:\/\/doi.org\/10.7150\/ijms.24981 (2018).","journal-title":"Int. J. Med. Sci."},{"key":"4855_CR40","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.795133","author":"H Wang","year":"2022","unstructured":"Wang, H. et al. SCG2 is a prognostic biomarker associated with immune infiltration and macrophage polarization in colorectal cancer. Front. Cell Dev. Biol. https:\/\/doi.org\/10.3389\/fcell.2021.795133 (2022).","journal-title":"Front. Cell Dev. Biol."},{"key":"4855_CR41","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1051063","author":"J Wang","year":"2022","unstructured":"Wang, J., He, X., Bai, Y., Du, G. & Cai, M. Identification and validation of novel biomarkers affecting bladder cancer immunotherapy via machine learning and its association with M2 macrophages. Front. Immunol. https:\/\/doi.org\/10.3389\/fimmu.2022.1051063 (2022).","journal-title":"Front. Immunol."},{"key":"4855_CR42","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.873871","author":"S Weng","year":"2022","unstructured":"Weng, S. et al. SCG2: A prognostic marker that pinpoints chemotherapy and immunotherapy in colorectal cancer. Front. Immunol. https:\/\/doi.org\/10.3389\/fimmu.2022.873871 (2022).","journal-title":"Front. Immunol."},{"key":"4855_CR43","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/s10495-023-01898-2","volume":"29","author":"J Zhou","year":"2024","unstructured":"Zhou, J. et al. Promoting effect and immunologic role of secretogranin II on bladder cancer progression via regulating MAPK and NF-\u03baB pathways. Apoptosis 29, 121\u2013141. https:\/\/doi.org\/10.1007\/s10495-023-01898-2 (2024).","journal-title":"Apoptosis"},{"key":"4855_CR44","doi-asserted-by":"publisher","first-page":"2006","DOI":"10.1001\/jama.2020.17601","volume":"324","author":"AT Lenis","year":"2020","unstructured":"Lenis, A. T., Lec, P. M. & Chamie, K. Bladder cancer. JAMA 324, 2006\u20132006. https:\/\/doi.org\/10.1001\/jama.2020.17601 (2020).","journal-title":"JAMA"},{"key":"4855_CR45","doi-asserted-by":"publisher","first-page":"S33","DOI":"10.1038\/551S33a","volume":"551","author":"M Grayson","year":"2017","unstructured":"Grayson, M. Bladder cancer. Nature 551, S33\u2013S33. https:\/\/doi.org\/10.1038\/551S33a (2017).","journal-title":"Nature"},{"key":"4855_CR46","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1038\/s41572-023-00468-9","volume":"9","author":"L Dyrskj\u00f8t","year":"2023","unstructured":"Dyrskj\u00f8t, L. et al. Bladder cancer. Nat. Rev. Dis. Primers. 9, 58. https:\/\/doi.org\/10.1038\/s41572-023-00468-9 (2023).","journal-title":"Nat. Rev. Dis. Primers."},{"key":"4855_CR47","doi-asserted-by":"publisher","first-page":"188904","DOI":"10.1016\/j.bbcan.2023.188904","volume":"1878","author":"SC Selvakumar","year":"2023","unstructured":"Selvakumar, S. C., Preethi, K. A. & Sekar, D. MicroRNAs as important players in regulating cancer through PTEN\/PI3K\/AKT signalling pathways. Biochim. Biophys. Acta Rev. Cancer 1878, 188904. https:\/\/doi.org\/10.1016\/j.bbcan.2023.188904 (2023).","journal-title":"Biochim. Biophys. Acta Rev. Cancer"},{"key":"4855_CR48","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.canlet.2014.01.016","volume":"346","author":"MK Shanmugam","year":"2014","unstructured":"Shanmugam, M. K. et al. Oleanolic acid and its synthetic derivatives for the prevention and therapy of cancer: Preclinical and clinical evidence. Cancer Lett. 346, 206\u2013216. https:\/\/doi.org\/10.1016\/j.canlet.2014.01.016 (2014).","journal-title":"Cancer Lett."},{"key":"4855_CR49","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1007\/s00204-015-1472-2","volume":"89","author":"EK Kim","year":"2015","unstructured":"Kim, E. K. & Choi, E.-J. Compromised MAPK signaling in human diseases: an update. Arch. Toxicol. 89, 867\u2013882. https:\/\/doi.org\/10.1007\/s00204-015-1472-2 (2015).","journal-title":"Arch. Toxicol."},{"key":"4855_CR50","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.1158\/1535-7163.Mct-18-0571","volume":"18","author":"JX Yu","year":"2019","unstructured":"Yu, J. X. et al. Phenotype-based screens with conformation-specific inhibitors reveal p38 gamma and delta as targets for HCC polypharmacology. Mol. Cancer Ther. 18, 1506\u20131519. https:\/\/doi.org\/10.1158\/1535-7163.Mct-18-0571 (2019).","journal-title":"Mol. Cancer Ther."},{"key":"4855_CR51","doi-asserted-by":"publisher","first-page":"2668","DOI":"10.3390\/ijms20112668","volume":"20","author":"H-F Chen","year":"2019","unstructured":"Chen, H.-F., Chuang, H.-C. & Tan, T.-H. Regulation of dual-specificity phosphatase (DUSP) ubiquitination and protein stability. Int. J. Mol. Sci. 20, 2668 (2019).","journal-title":"Int. J. Mol. Sci."},{"key":"4855_CR52","doi-asserted-by":"publisher","DOI":"10.3389\/fchbi.2024.1385560","author":"A Imhoff","year":"2024","unstructured":"Imhoff, A. et al. Structural and kinetic characterization of DUSP5 with a di-phosphorylated tripeptide substrate from the ERK activation loop. Front. Chem. Biol. https:\/\/doi.org\/10.3389\/fchbi.2024.1385560 (2024).","journal-title":"Front. Chem. Biol."},{"key":"4855_CR53","doi-asserted-by":"publisher","first-page":"1794","DOI":"10.1016\/j.cellsig.2009.07.015","volume":"21","author":"A Kucharska","year":"2009","unstructured":"Kucharska, A., Rushworth, L. K., Staples, C., Morrice, N. A. & Keyse, S. M. Regulation of the inducible nuclear dual-specificity phosphatase DUSP5 by ERK MAPK. Cell. Signal. 21, 1794\u20131805. https:\/\/doi.org\/10.1016\/j.cellsig.2009.07.015 (2009).","journal-title":"Cell. Signal."},{"key":"4855_CR54","doi-asserted-by":"publisher","first-page":"3135","DOI":"10.1007\/s11357-024-01061-y","volume":"46","author":"C Tang","year":"2024","unstructured":"Tang, C. et al. Impact of knockout of dual-specificity protein phosphatase 5 on structural and mechanical properties of rat middle cerebral arteries: Implications for vascular aging. GeroScience 46, 3135\u20133147. https:\/\/doi.org\/10.1007\/s11357-024-01061-y (2024).","journal-title":"GeroScience"},{"key":"4855_CR55","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1111\/j.1476-5381.2010.00873.x","volume":"160","author":"JC McGrath","year":"2010","unstructured":"McGrath, J. C., Drummond, G., McLachlan, E., Kilkenny, C. & Wainwright, C. Guidelines for reporting experiments involving animals: The ARRIVE guidelines. Br. J. Pharmacol. 160, 1573\u20131576 (2010).","journal-title":"Br. J. Pharmacol."},{"key":"4855_CR56","doi-asserted-by":"publisher","unstructured":"International guiding principles for biomedical research involving animals issued by CIOMS. Vet. Q. 8, 350\u2013352 https:\/\/doi.org\/10.1080\/01652176.1986.9694068 (1986).","DOI":"10.1080\/01652176.1986.9694068"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-04855-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-04855-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-04855-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,5]],"date-time":"2025-06-05T03:22:14Z","timestamp":1749093734000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-04855-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,5]]},"references-count":56,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4855"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-04855-y","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,5]]},"assertion":[{"value":"24 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"19723"}}